跳转至内容

Dear Customer:

The current international situation is complex and volatile, and uncertain tariff policies may potentially impact our product prices. Given these uncertainties, we value your understanding regarding order-related matters.

If you decide to place an order during this period, we reserve the right to adjust the price based on the evolving situation. We understand that market changes may cause inconvenience. We will negotiate with you if there’s a significant price fluctuation due to tariff policy changes before the order’s actual delivery, and in such cases we may adjust or cancel the order as necessary.

We are planning system maintenance between Friday, Apr 11 at 9:00 PM CDT and Saturday, Apr 12 at 9:00 AM CDT. This will impact both web and offline transactions, including online orders, quotes, price and availability checks, and order status inquiries. We apologize for any inconvenience.

Merck
CN
  • Neurotrophin Receptors TrkA, p75NTR, and Sortilin Are Increased and Targetable in Thyroid Cancer.

Neurotrophin Receptors TrkA, p75NTR, and Sortilin Are Increased and Targetable in Thyroid Cancer.

The American journal of pathology (2017-10-19)
Sam Faulkner, Philip Jobling, Christopher W Rowe, S M Rodrigues Oliveira, Severine Roselli, Rick F Thorne, Christopher Oldmeadow, John Attia, Chen Chen Jiang, Xu Dong Zhang, Marjorie M Walker, Hubert Hondermarck
摘要

Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.

材料
货号
品牌
产品描述

Sigma-Aldrich
抗肌动蛋白抗体 兔抗, affinity isolated antibody, buffered aqueous solution
登录查看公司和协议定价
货号包装规格是否有货价格数量
100 μL
预计发货时间 2025年4月14日
详情...
¥5,294.29
0.2 mL
预计发货时间 2025年6月12日
详情...
¥7,940.75
Sigma-Aldrich
QCM ECMatrix Cell Invasion Assay, 24-well (8 µm), fluorimetric, The Cell Invasion Assay Kit kuses a 24 well plate with 8 um pores, which is ideal for evaluation of invasive tumor cells.
登录查看公司和协议定价
货号包装规格是否有货价格数量
24 assays
预计发货时间 2025年5月26日
详情...
¥6,570.81
Sigma-Aldrich
Anti-Nerve Growth Factor Antibody, pro, serum, Chemicon®
登录查看公司和协议定价
货号包装规格是否有货价格数量
100 μL
预计发货时间 2025年5月06日
详情...
¥4,239.58
Sigma-Aldrich
MISSION® esiRNA, targeting human NTRK1
登录查看公司和协议定价
货号包装规格是否有货价格数量
20 μg
预计发货时间 2025年7月04日
详情...
¥3,096.05
50 μg
预计发货时间 2025年7月04日
详情...
¥5,521.21